The Role of Heterogeneous Nuclear Ribonucleoprotein K in the Progression of Chronic Myeloid Leukemia

Overview

Journal Med Oncol

Publisher Springer

Specialty Oncology

Date 2009 Aug 5

PMID 19653139

Citations 10

Authors

Qingfeng Du

Li Wang

Hongqian Zhu

Song Zhang

Lulu Xu

Weiyang Zheng

Xiaoli Liu

Affiliations

Soon will be listed here.

Abstract

Chronic myeloid leukemia (CML) is a neoplastic disease of the hematopoietic stem cell. Heterogeneous nuclear ribonucleoprotein K (hnRNPK) may up-regulate the transcriptional activity of some oncogenes in cancerous cells. The aim of this study was to verify the expression pattern of hnRNPK in patients with CML, to explore its association with BCR-ABL and some abnormal signaling pathways, and to discover how hnRNPK contributes to the progression of CML. In this study, 15 patients with CML (9 in chronic phase and 6 in blast crisis) were enrolled in this study. The expression of hnRNPK in mononuclear cells (MNCs) from these patients was detected by Western blotting and fluorimeter-based quantitative real-time reverse transcriptase polymerase chain reaction. hnRNPK expression levels in K562 cell line and imatinib-resistant leukemic cell line K562R, following the treatments with the inhibitors of Ras-MAPK (PD98059), PI3K/AKT (LY294002), JAK/STAT (AG490) signaling pathways, and BCR-ABL [imatinib mesylate (IM)], were also determined. As the results, the overexpression of hnRNPK in protein and gene patterns was detected in MNCs from patients with CML comparing with normal donors. Especially, its level in MNCs from patients with CML-blast crisis was significantly higher than in CML-chronic phase cells (P < 0.01). After the treatment with PD98059 (at 4, 8, 24, and 48 h) and IM (at 48 h), the expression levels of hnRNPK in leukemic cell lines were decreased, comparing with DMSO control group (P < 0.05). In conclusion, the results suggest that the overexpression of hnRNPK, which is regulated by BCR-ABL and Ras-MAPK signaling pathways, may promote the progression of CML. hnRNPK would be a potential marker and therapeutic target of CML evolution.

Citing Articles

DNA- and RNA-Binding Proteins Linked Transcriptional Control and Alternative Splicing Together in a Two-Layer Regulatory Network System of Chronic Myeloid Leukemia.

Wang C, Zong X, Wu F, Leung R, Hu Y, Qin J Front Mol Biosci. 2022; 9:920492.

PMID: 36052164 PMC: 9425088. DOI: 10.3389/fmolb.2022.920492.

HNRNPH1 Is a Novel Regulator Of Cellular Proliferation and Disease Progression in Chronic Myeloid Leukemia.

Liu M, Yang L, Liu X, Nie Z, Zhang X, Lu Y Front Oncol. 2021; 11:682859.

PMID: 34295818 PMC: 8290130. DOI: 10.3389/fonc.2021.682859.

Crosstalk between hnRNP K and SET in ATRA-induced differentiation in acute promyelocytic leukemia.

Padovani K, Goto R, Brigliadori Fugio L, Garcia C, Alves V, Brassesco M FEBS Open Bio. 2021; 11(7):2019-2032.

PMID: 34058077 PMC: 8255839. DOI: 10.1002/2211-5463.13210.

Involvement of the Wnt/β-Catenin signaling pathway in the heterogenous nuclear ribonucleoprotein K-driven inhibition of proliferation and migration in head and neck squamous cell carcinoma.

Liu H, Chen X, Yang X, Li M, Zhang W, Zhang G Oncol Lett. 2020; 20(6):394.

PMID: 33193854 PMC: 7656118. DOI: 10.3892/ol.2020.12257.

Depression of oncogenecity by dephosphorylating and degrading BCR-ABL.

Gao M, Huang Z, Tao K, Xiao Q, Wang X, Cao W Oncotarget. 2016; 8(2):3304-3314.

PMID: 27926512 PMC: 5356883. DOI: 10.18632/oncotarget.13754.

References

Notari M, Neviani P, Santhanam R, Blaser B, Chang J, Galietta A . A MAPK/HNRPK pathway controls BCR/ABL oncogenic potential by regulating MYC mRNA translation. Blood. 2005; 107(6):2507-16. PMC: 1895740. DOI: 10.1182/blood-2005-09-3732. View

Ruan G, Qin Y, Chen S, Li J, Ma X, Chang Y . Abnormal expression of the programmed cell death 5 gene in acute and chronic myeloid leukemia. Leuk Res. 2006; 30(9):1159-65. DOI: 10.1016/j.leukres.2005.12.028. View

Cowley S, PATERSON H, Kemp P, Marshall C . Activation of MAP kinase kinase is necessary and sufficient for PC12 differentiation and for transformation of NIH 3T3 cells. Cell. 1994; 77(6):841-52. DOI: 10.1016/0092-8674(94)90133-3. View

Vlahos C, Matter W, Hui K, Brown R . A specific inhibitor of phosphatidylinositol 3-kinase, 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one (LY294002). J Biol Chem. 1994; 269(7):5241-8. View

Ren R . Mechanisms of BCR-ABL in the pathogenesis of chronic myelogenous leukaemia. Nat Rev Cancer. 2005; 5(3):172-83. DOI: 10.1038/nrc1567. View

Ostareck-Lederer A, Ostareck D, Cans C, Neubauer G, Bomsztyk K, Superti-Furga G . c-Src-mediated phosphorylation of hnRNP K drives translational activation of specifically silenced mRNAs. Mol Cell Biol. 2002; 22(13):4535-43. PMC: 133888. DOI: 10.1128/MCB.22.13.4535-4543.2002. View

Soverini S, Martinelli G, Rosti G, Bassi S, Amabile M, Poerio A . ABL mutations in late chronic phase chronic myeloid leukemia patients with up-front cytogenetic resistance to imatinib are associated with a greater likelihood of progression to blast crisis and shorter survival: a study by the GIMEMA Working Party.... J Clin Oncol. 2005; 23(18):4100-9. DOI: 10.1200/JCO.2005.05.531. View

Perrotti D, Calabretta B . Translational regulation by the p210 BCR/ABL oncoprotein. Oncogene. 2004; 23(18):3222-9. DOI: 10.1038/sj.onc.1207543. View

Pocaly M, Lagarde V, Etienne G, Ribeil J, Claverol S, Bonneu M . Overexpression of the heat-shock protein 70 is associated to imatinib resistance in chronic myeloid leukemia. Leukemia. 2006; 21(1):93-101. DOI: 10.1038/sj.leu.2404463. View

10.

Barnes D, Palaiologou D, Panousopoulou E, Schultheis B, Yong A, Wong A . Bcr-Abl expression levels determine the rate of development of resistance to imatinib mesylate in chronic myeloid leukemia. Cancer Res. 2005; 65(19):8912-9. DOI: 10.1158/0008-5472.CAN-05-0076. View

11.

Ye D, Wolff N, Li L, Zhang S, Ilaria Jr R . STAT5 signaling is required for the efficient induction and maintenance of CML in mice. Blood. 2006; 107(12):4917-25. PMC: 1895818. DOI: 10.1182/blood-2005-10-4110. View

12.

Rosen L, Ginty D, Weber M, Greenberg M . Membrane depolarization and calcium influx stimulate MEK and MAP kinase via activation of Ras. Neuron. 1994; 12(6):1207-21. DOI: 10.1016/0896-6273(94)90438-3. View

13.

Milella M, Precupanu C, Gregorj C, Ricciardi M, Petrucci M, Kornblau S . Beyond single pathway inhibition: MEK inhibitors as a platform for the development of pharmacological combinations with synergistic anti-leukemic effects. Curr Pharm Des. 2005; 11(21):2779-95. DOI: 10.2174/1381612054546842. View

14.

Bomsztyk K, Denisenko O, Ostrowski J . hnRNP K: one protein multiple processes. Bioessays. 2004; 26(6):629-38. DOI: 10.1002/bies.20048. View

15.

Druker B, Guilhot F, OBrien S, Gathmann I, Kantarjian H, Gattermann N . Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. N Engl J Med. 2006; 355(23):2408-17. DOI: 10.1056/NEJMoa062867. View

16.

Calabretta B, Perrotti D . The biology of CML blast crisis. Blood. 2004; 103(11):4010-22. DOI: 10.1182/blood-2003-12-4111. View

17.

Meshinchi S, Stirewalt D, Alonzo T, Zhang Q, Sweetser D, Woods W . Activating mutations of RTK/ras signal transduction pathway in pediatric acute myeloid leukemia. Blood. 2003; 102(4):1474-9. DOI: 10.1182/blood-2003-01-0137. View

18.

Perrotti D, Cesi V, Trotta R, Guerzoni C, Santilli G, Campbell K . BCR-ABL suppresses C/EBPalpha expression through inhibitory action of hnRNP E2. Nat Genet. 2001; 30(1):48-58. DOI: 10.1038/ng791. View

19.

Alessi D, Saito Y, Campbell D, Cohen P, Sithanandam G, Rapp U . Identification of the sites in MAP kinase kinase-1 phosphorylated by p74raf-1. EMBO J. 1994; 13(7):1610-9. PMC: 394991. DOI: 10.1002/j.1460-2075.1994.tb06424.x. View

20.

Carpenter B, Mackay C, Alnabulsi A, MacKay M, Telfer C, Melvin W . The roles of heterogeneous nuclear ribonucleoproteins in tumour development and progression. Biochim Biophys Acta. 2005; 1765(2):85-100. DOI: 10.1016/j.bbcan.2005.10.002. View